BioLattice, a Philadelphia-based tissue engineering startup developing regenerative solutions for corneal blindness, has raised $575,000 in a new funding round as it advances toward preclinical and regulatory milestones for its engineered cornea platform.

The latest investment brings additional capital to a company that has steadily progressed from grant-backed research into early venture financing. The round reflects continued investor interest in BioLattice’s core technology, which aims to replace or augment donor corneal tissue with a biomaterial-based alternative designed to improve long-term transplant outcomes and address global shortages in eye tissue availability.

The funding follows a broader history of non-dilutive and early-stage support for the company, including federal research grants such as a National Science Foundation Small Business Innovation Research (SBIR) Phase I award received in 2023. BioLattice has also benefited from regional life sciences initiatives and accelerator programs that helped advance its early prototypes and validate its corneal repair approach in preclinical settings.

While the company has not publicly disclosed a large institutional venture capital syndicate for its latest round, earlier financing activity has included backing from deep-tech and life sciences-focused investors such as IndieBio, SOSV, and The Enterprise Center Capital, along with participation from non-dilutive grant programs including the U.S. National Science Foundation. These early supporters have played a key role in enabling BioLattice to transition from academic research into commercial product development.

BioLattice was founded by biomedical engineer Amelia Zellander, who began developing the technology behind the company’s corneal substitute after years of academic and pharmaceutical research in tissue engineering. The startup’s lead product, an engineered corneal scaffold designed to mimic the structure and function of human corneal tissue, is intended to address both the shortage of donor corneas and the long-term complications associated with traditional transplant procedures.

The company’s approach focuses on creating a bio-integrated implant that can support tissue regeneration while maintaining optical clarity, with potential applications in treating corneal blindness caused by injury, disease, or degenerative conditions. According to industry data cited by the company, millions of patients worldwide suffer from corneal vision loss each year, yet only a fraction receive transplant surgery due to limited donor supply.

BioLattice’s funding trajectory has also been supported by competitive awards and pitch-based financing, including startup competitions and accelerator programs such as HiveBio. These programs have provided both capital and validation, helping the company refine its research roadmap and attract early attention from investors in the regenerative medicine sector.

The newly reported $575,000 raise is expected to support continued development of BioLattice’s engineered cornea technology, including refinement of biomaterial composition, expansion of laboratory testing, and preparation for future regulatory submissions. The company is also working toward scaling its research partnerships and advancing toward in vivo studies as part of its long-term commercialization strategy.

As BioLattice moves deeper into the clinical development pipeline, it remains positioned within a growing segment of biotech startups focused on tissue regeneration and organ repair. The company’s ability to transition from grant-funded research to structured venture investment reflects broader trends in life sciences funding, where early-stage biotech firms increasingly rely on blended capital sources to bridge the gap between discovery and commercialization.

With fresh funding secured and prior grant-backed research foundations in place, BioLattice continues to pursue its mission of developing an accessible and scalable alternative to donor corneal transplantation, aiming to reshape treatment options for patients suffering from irreversible corneal damage.

Related Articles